Gosebruch promises to sail the ship with its oars of hardship

Introduction

Henry Gosebruch, a G100 Next Gen graduate a valuable member of the board of directors at Acelyrin, known for its commendable work at AbbVie as a Former Executive Vice President and Chief Strategy Officer. The acquisitions, partnership management, and other business development specialist Gosebruch holds extensive experience in the vast healthcare industry. His intellectuality and thoughtfulness make his presence worthy in the healthcare sector.

Announcement

Henry Gosebruch is now the CEO of Galapagos, which holds a capital worth $3.5 billion, waiting to use it wisely and smartly. His mindset is broader due to his experience and observation, after years of addressing old biotech challenges and hardship. Gosebruch will be discovering a whole new direction, as he has seen the company’s disappointment and struggle after multiple clinical failures, fluctuations in leadership command and FDA rejections.

Swallowing the past unfavorable failures, Galapagos will witness a new sunshine with the reconstruction of individuals' lives through required modifications in the pattern of the clinical trials.

How does Gosebruch see this opportunity?

In April 2025, he was called to form a brand new pipeline and expand the portfolio. So his exact role might be different on paper, but he analysed this opportunity as a business opportunity altogether. Later, the company changed its decision and declared Stoffels’ selection. The Galapagos organisation chose Gosebruch as the CEO of the main division of the company. With this position, too, he can continue searching for a new pipeline.

This decision sharpened the opportunity and let Gosebruch enter with double the power for his mission. Galapagos was planning to gather partners for its existing programs, involving Phase 2 CD19 CAR T GLPG5101 for blood cancer, but hasn’t yet met the right and sensible proposal.

Plans

Galapagos do have an effective pipeline for decades, involving a TYK2 small molecule for immunology known as ‘GLPG3667’. This therapy is now used in Phase 2 trials for dermatomyositis and lupus erythematosus. Gosebruch said, “The GLPG3667 greatly survived back those days but might not stay in Galapagos hands.”

He further continued, “Currently, we’re thinking whether to or not reconstruct around that same asset, as we don’t have a huge development team or measurably big infrastructure as well, which we had back in the day. Should we join hands with the partners by building a partnership deal with those who already have these things?”